Apoptotic Regulators and Its Clinical Implications in Mammary Carcinoma

Chapter

Abstract

Today, this is an established fact that like other organs, normal breast development is also used to be monitored by a balance between cell proliferation and apoptosis. As a consequence, tumor growth is not an outcome of abnormal cell proliferation only, but of reduced apoptosis, too. Apoptosis or programmed cell death maintains the integrity of a healthy individual, while dysregulation of this mechanism becomes crucial for the pathophysiology of tumorigenesis. Bcl-2 family of proteins, caspaes, IAP family of proteins, TNF superfamily members are the important regulators of apoptotic signaling pathways. Therefore, several therapeutic agents have been exploited targeting these apoptotic pathways. The review has been concentrated on physiology and pathophysiology of different apoptotic regulators and their therapeutic intervention towards breast cancer.

Keywords

Death Induce Signaling Complex Extrinsic Apoptotic Pathway Tumor Necrosis Factor Receptor Superfamily Apoptotic Regulator Mammary Gland Involution 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Adams JM, Cory S (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26:1324–1337CrossRefPubMedGoogle Scholar
  2. Aird KM, Ding X, Baras A et al (2008) Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. Mol Cancer Ther 7:38–47CrossRefPubMedGoogle Scholar
  3. Anderson GM, Nakada MT, DeWitte M (2004) Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 4:314–320CrossRefPubMedGoogle Scholar
  4. Baldwin AS (2001) Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 197:241–246CrossRefGoogle Scholar
  5. Ballif BA, Blenis J (2001) Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ 12:397–408PubMedGoogle Scholar
  6. Barnhart BC, Alappat EC, Peter ME (2003) The CD95 type I/type II model. Semin Immunol 15(3):185–193CrossRefPubMedGoogle Scholar
  7. Beroukhim R, Mermel C, Porter D et al (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463(7283):899–905CrossRefPubMedGoogle Scholar
  8. Blajeski AL, Kottke TJ, Kaufmann SH (2001) A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines. Exp Cell Res 270:277–288CrossRefPubMedGoogle Scholar
  9. Bodmer JL, Schneider P, Tschopp J (2002) The molecular architecture of the TNF superfamily. Trends Biochem Sci 27(1):19–26CrossRefPubMedGoogle Scholar
  10. Cheng EH, Wei MC, Weiler S et al (2001) BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK mediated mitochondrial apoptosis. Mol Cell 8:705–711CrossRefPubMedGoogle Scholar
  11. Chevalier B, Fumoleau P, Kerbrat P et al (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a Phase 2 trial of the clinical screening cooperative group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13:314–322Google Scholar
  12. Chinnaiyan AM, Prasad U, Shankar S et al (2000) Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A 97(4):1754–1759CrossRefPubMedGoogle Scholar
  13. Cottart CH, Nivet-Antoine V, Laguillier-Morizot C et al (2010) Resveratrol bioavailability and toxicity in humans. Mol Nutr Food Res 54(1):7–16CrossRefPubMedGoogle Scholar
  14. Cox A, Dunning AM, Garcia-Closas M et al (2007) A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 39:352–358CrossRefPubMedGoogle Scholar
  15. Danial NN (2007) BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res 13:7254–7263CrossRefPubMedGoogle Scholar
  16. Danial NN, Korsmeyer SJ (2004) Cell death: critical control points. Cell 116:205–219CrossRefPubMedGoogle Scholar
  17. Datta R, Oki E, Endo K et al (2000) XIAP regulates DNA damage-induced apoptosis downstream of caspase-9 cleavage. J Biol Chem 275:31733–31738CrossRefPubMedGoogle Scholar
  18. De Azevedo WF, Leclerc S, Meijer L et al (1997) Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 243:518–526CrossRefPubMedGoogle Scholar
  19. Debatin KM (2004) Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 53(3):153–159CrossRefPubMedGoogle Scholar
  20. Deveraux QL, Reed JC (1999) IAP family proteins: suppressors of apoptosis. Genes Dev 13:239–252CrossRefPubMedGoogle Scholar
  21. Deveraux QL, Reed JC, Salvesen GS (2000) Caspases and their natural inhibitors as therapeutic targets for regulating apoptosis. In: von der Helm K, Korant BD, Cheronis JC (eds) Handbook of experimental pharmacology – proteases as targets for therapy, vol 140(3). Springer, Berlin/Heidelberg/New York, pp 329–340CrossRefGoogle Scholar
  22. Earnshow WC, Martins LM, Kaufmann SH (1999) Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem 68:383–424CrossRefGoogle Scholar
  23. Eckelman BP, Salvesen GS (2006) The human anti-apoptotic proteins cIAP1 and cIAP2 bind but do not inhibit caspases. J Biol Chem 281:3254–3260CrossRefPubMedGoogle Scholar
  24. Eckelman BP, Salvesen GS, Scott FL (2006) Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 7:988–994CrossRefPubMedGoogle Scholar
  25. Fadeel B, Zhivotovsky B, Orrenius S (1999) All along the watchtower: on the regulation of apoptosis regulators. FASEB J 13:1647–1657PubMedGoogle Scholar
  26. Fernández de Corres L (1984) Contact dermatitis from Frullania, Compositae and other plants. Contact Dermatitis 11(2):74–79CrossRefPubMedGoogle Scholar
  27. Foster FM, Owens TW, Tanianis-Hughes J (2009) Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. Breast Cancer Res 11(3):R41CrossRefPubMedGoogle Scholar
  28. Fulda S (2009) Tumor resistance to apoptosis. Int J Cancer 124:511–515CrossRefPubMedGoogle Scholar
  29. Furth PA (1999) Apoptosis and the development of breast cancer. In: Bowcock AM (ed) Breast cancer: molecular genetics, pathogenesis, and therapeutics. Humana Press, Totowa, pp 171–180Google Scholar
  30. Geske FJ, Gerschenson IE (2001) The biology of apoptosis. Hum Pathol 32:1029–1038CrossRefPubMedGoogle Scholar
  31. Giam M, Huang DC, Bouillet P (2008) BH3-only proteins and their roles in programmed cell death. Oncogene 27(Suppl 1):S128–S136CrossRefPubMedGoogle Scholar
  32. Gross A, McDonnell JM, Korsmeyer SJ (1999) Bcl-2 family members and the mitochondria in apoptosis. Genes Dev 13:1899–1911CrossRefPubMedGoogle Scholar
  33. Gruss HJ, Dower SK (1995) Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas. Blood 85(12):3378–3404PubMedGoogle Scholar
  34. Guicciardi ME, Gores GJ (2009) Life and death by death receptors. FASEB J 23:1625–1637CrossRefPubMedGoogle Scholar
  35. Herr I, Debatin KM (2001) Cellular stress response and apoptosis in cancer therapy. Blood 98:2603–2614CrossRefPubMedGoogle Scholar
  36. Hiraga T, Williams PJ, Mundy GR et al (2001) The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 61:4418–4424PubMedGoogle Scholar
  37. Holcik M, Korneluk RG (2001) XIAP, the guardian angel. Nat Rev Mol Cell Biol 7:550–556CrossRefGoogle Scholar
  38. Holkova B, Perkins EB, Ramakrishnan V et al (2011) Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res 17(10):3388–3397CrossRefPubMedGoogle Scholar
  39. Holmes FA, Walters RS, Theriault RL et al (1991) Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797–1805CrossRefPubMedGoogle Scholar
  40. Hui A-M, Zhang W, Chen W et al (2004) Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells. Cancer Res 64:9115–9123CrossRefPubMedGoogle Scholar
  41. Ioachim HL, Decuseara R, Giancotti F et al (2005) FAS and FAS-L expression by tumor cells and lymphocytes in breast carcinomas and their lymph node metastases. Pathol Res Pract 200:743–751CrossRefPubMedGoogle Scholar
  42. Jacobson MD, Weil M, Raff MC (1997) Programmed cell death in animal development. Cell 88:347–354CrossRefPubMedGoogle Scholar
  43. Jäger R, Herzer U, Schenkel J et al (1997) Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice. Oncogene 15:1787–1795CrossRefPubMedGoogle Scholar
  44. Jin Z, El-Deiry WS (2005) Overview of cell death signaling pathways. Cancer Biol Ther 4:139–163CrossRefPubMedGoogle Scholar
  45. Jones SE, Erban J, Overmoyer B (2005) Randomized Phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23(24):5542–5551CrossRefPubMedGoogle Scholar
  46. Kaufamnn SH, Earnshaw WC (2000) Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256:42–49CrossRefGoogle Scholar
  47. Keane MM, Ettenberg SA, Lowrey GA et al (1996) Fas expression and function in normal and malignant breast cell lines. Cancer Res 56:4791–4798PubMedGoogle Scholar
  48. Kerr JF, Wyllie AH, Currie AR (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26:239–257CrossRefPubMedGoogle Scholar
  49. Kischkel FC, Lawrence DA, Tinel A et al (2001) Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 276:46639–46646CrossRefPubMedGoogle Scholar
  50. Kluck RM, Bossy-Wetzel E, Green DR et al (1997) The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275:1132–1136CrossRefPubMedGoogle Scholar
  51. Krajewski S, Krajewska M, Shabaik A et al (1994) Immunohistochemical determination of in vivo distribution of bax, a dominant inhibitor of bcl-2. Am J Pathol 145:1323–1333PubMedGoogle Scholar
  52. Krajewski S, Krajewska M, Turner BC et al (1999) Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer 6:29–40CrossRefPubMedGoogle Scholar
  53. Kroemer G, Reed JC (2000) Mitochondrial control of cell death. Nat Med 6:513–519CrossRefPubMedGoogle Scholar
  54. LaCasse EC, Mahoney DJ, Cheung HH et al (2008) IAP-targeted therapies for cancer. Oncogene 27:6252–6275CrossRefPubMedGoogle Scholar
  55. Lavrik IN, Golks A, Baumann S et al (2006) Caspase-2 is activated at the CD95 death-inducing signaling complex in the course of CD95-induced apoptosis. Blood 108(2):559–565CrossRefPubMedGoogle Scholar
  56. Le Blanc HN, Ashkenazi A (2003) Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10:66–75CrossRefGoogle Scholar
  57. Le Tourneau C, Faivre S, Laurence V et al (2010) Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer 46(18):3243–3250CrossRefPubMedGoogle Scholar
  58. Lee S, Yang W, Lan K-H et al (2002) Enhanced sensitization to taxol-induced apoptosis by Herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res 62:5703–5710PubMedGoogle Scholar
  59. Li J, Yuan J (2008) Caspases in apoptosis and beyond. Oncogene 27:6194–6206CrossRefPubMedGoogle Scholar
  60. Lund LR, Romer J, Thomasset N et al (1996) Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways. Development 122:181–193PubMedGoogle Scholar
  61. Mace PD, Shirley S, Day CL (2010) Assembling the building blocks: structure and function of inhibitor of apoptosis proteins. Cell Death Differ 17:46–53CrossRefPubMedGoogle Scholar
  62. Martinou JC, Green DR (2001) Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol 2:63–67CrossRefPubMedGoogle Scholar
  63. Medina P, Silvente-Poirot S, Poirot M (2009) Tamoxifen and AEBS ligands induced apoptosis and autophagy in breast cancer cells through the stimulation of sterol accumulation. Autophagy 5(7):1066–1067CrossRefPubMedGoogle Scholar
  64. Meijer L, Borgne A, Mulner O et al (1997) (1997) Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243:527–536CrossRefPubMedGoogle Scholar
  65. Mgbonyebi OP, Russo J, Russo IH (1999) Roscovitine induces cell death and morphological changes indicative of apoptosis in MDA-MB-231 breast cancer cells. Cancer Res 59:1903–1910PubMedGoogle Scholar
  66. Micheau O, Tschopp J (2003) Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114(2):181–190CrossRefPubMedGoogle Scholar
  67. Motoyama N, Wang FP, Roth KA et al (1995) Massive cell death of immature hematopoietic cells and neurons in Bcl-x deficient mice. Science 267:1506–1510CrossRefPubMedGoogle Scholar
  68. Motoyama N, Kimura T, Takahashi T et al (1999) Bcl-x prevents apoptotic cell death of both primitive and definitive erythrocytes at the end of maturation. J Exp Med 189:1691–1698CrossRefPubMedGoogle Scholar
  69. Muchmore SW, Sattler M, Liang H et al (1996) X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381:335–341CrossRefPubMedGoogle Scholar
  70. Mullauer L, Mosberger I, Grusch M et al (2000) Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. J Pathol 190:20–30CrossRefPubMedGoogle Scholar
  71. Nakayama K-I, Nakayama K, Izumi N et al (1993) Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice. Science 261:1584–1588CrossRefPubMedGoogle Scholar
  72. Nakayama K, Nakayama K-I, Negishi I et al (1994) Targeted disruption of bcl-2ab in mice: occurrence of gray hair, polycystic kidney disease, and lymphocytopenia. Proc Natl Acad Sci U S A 91:3700–3704CrossRefPubMedGoogle Scholar
  73. Nakshatri H, Susan E, Rice SE, Bhat-Nakshatri P (2004) Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 23:7330–7344CrossRefPubMedGoogle Scholar
  74. Newton K, Strasser A (2001) Cell death control in lymphocytes. Adv Immunol 76:179–226CrossRefGoogle Scholar
  75. Oliveras-Ferraros C, Vazquez-Martin A, Cufí S et al (2011) Inhibitor of apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies. Biochem Biophys Res Commun 407:412–419CrossRefPubMedGoogle Scholar
  76. Olsson M, Zhivotovsky B (2011) Caspases and cancer. Cell Death Differ 18:1441–1449CrossRefPubMedGoogle Scholar
  77. Onitilo AA, Doi SA, Engel JM et al (2012) Clustering of venous thrombosis events at the start of tamoxifen therapy in breast cancer: a population-based experience. Thromb Res 130(1):27–31CrossRefPubMedGoogle Scholar
  78. Pandey PR, Okuda H, Watabe M et al (2011) Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. Breast Cancer Res Treat 130:387–398CrossRefPubMedGoogle Scholar
  79. Pegram MD, Konecny GE, O’Callaghan C et al (2004) Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96(10):739–749CrossRefPubMedGoogle Scholar
  80. Peter ME, Krammer PH (2003) The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 10(1):26–35CrossRefPubMedGoogle Scholar
  81. Pfeffer K, Matsuyama T, Kundig TM et al (1993) Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73:457–467CrossRefPubMedGoogle Scholar
  82. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672CrossRefPubMedGoogle Scholar
  83. Plati J, Bucur O, Far RK (2011) Apoptotic cell signaling in cancer progression and therapy. Integr Biol 3:279–296CrossRefGoogle Scholar
  84. Pozo-Guisado E, Merino JM, Mulero-Navarro S et al (2005) Resveratrol-induced apoptosis in MCF-7 human breast cancer cells involves a caspase-independent mechanism with downregulation of Bcl-2 and NF-kB. Int J Cancer 115:74–84CrossRefPubMedGoogle Scholar
  85. Pozzi S, Raje N (2011) The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. Oncologist 16(5):651–662CrossRefPubMedGoogle Scholar
  86. Print CG, Loveland KL, Gibson L et al (1998) Apoptosis regulator Bcl-w is essential for spermatogenesis but appears otherwise redundant. Proc Natl Acad Sci U S A 95:12424–12431CrossRefPubMedGoogle Scholar
  87. Pullan S, Wilson J, Metcalfe A et al (1996) Requirement of basement membrane for the suppression of programmed cell death in mammary epithelium. J Cell Sci 109:631–642PubMedGoogle Scholar
  88. Rathmell JC, Thompson CB (1999) The central effectors of cell death in the immune system. Annu Rev Immunol 17:781–828CrossRefPubMedGoogle Scholar
  89. Reed JC (2001) The surviving saga goes in vivo. J Clin Invest 108:965–969CrossRefPubMedGoogle Scholar
  90. Reginato MJ, Mills KR, Becker EB et al (2005) Bim regulation of lumen formation in cultured mammary epithelial acini is targeted by oncogenes. Mol Cell Biol 25:4591–4601CrossRefPubMedGoogle Scholar
  91. Riggins RB, Zwart A, Nehra R et al (2005) The nuclear factor KB inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant) – induced apoptosis in antiestrogen-resistant breast cancer cells. Mol Cancer Ther 4:33–41PubMedGoogle Scholar
  92. Rowinsky EK (2005) Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 23:9394–9407CrossRefPubMedGoogle Scholar
  93. Saikumar P, Dong Z, Mikhailov V et al (1999) Apoptosis: definition, mechanisms, and relevance to disease. Am J Med 107:489–506CrossRefPubMedGoogle Scholar
  94. Sasaki A, Boyse BF, Story B et al (1995) Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55:3551–3557PubMedGoogle Scholar
  95. Scaffidi C, Fulda S, Srinivasan A et al (1998) Two CD95 (APO-1/Fas) signaling pathways. EMBO J 17:1675–1687CrossRefPubMedGoogle Scholar
  96. Schwartz GK, Farsi K, Maslak P et al (1997) Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin Cancer Res 3:1467–1472PubMedGoogle Scholar
  97. Senaratne SG, Pirianov G, Mansi JL et al (2000) Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82(8):1459–1468CrossRefPubMedGoogle Scholar
  98. Shibata MA, Liu ML, Knudson MC et al (1999) Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/ SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage. EMBO J 18:2692–2701CrossRefPubMedGoogle Scholar
  99. Simstein R, Burow M, Parker A et al (2003) Apoptosis, chemoresistance, and breast cancer: insights from the MCF-7 cell model system. Exp Biol Med (Maywood) 228(9):995–1003Google Scholar
  100. Singh TR, Shankar S, Chen X et al (2003) Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 63:5390–5400PubMedGoogle Scholar
  101. Singh N, Nigam M, Ranjan V et al (2009) Caspase mediated enhanced apoptotic action of cyclophosphamide and resveratrol-treated MCF-7 cells. J Pharmacol Sci 109:473–485CrossRefPubMedGoogle Scholar
  102. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182CrossRefPubMedGoogle Scholar
  103. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712CrossRefPubMedGoogle Scholar
  104. Song J, Sapi E, Brown W et al (2000) Roles of Fas and Fas ligand during mammary gland remodeling. J Clin Invest 106:1209–1220CrossRefPubMedGoogle Scholar
  105. Sprick MR, Weigand MA, Rieser E et al (2000) FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12:599–609CrossRefPubMedGoogle Scholar
  106. Stein T, Salomonis N, Gusterson BA (2007) Mammary gland involution as a multi-step process. J Mammary Gland Biol Neoplasia 12:25–35CrossRefPubMedGoogle Scholar
  107. Sturm I, Kohne CH, Wolff G et al (1999) Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol 17:1364–1374PubMedGoogle Scholar
  108. Suliman A, Lam A, Datta R et al (2000) Intracellular mechanisms of TRAIL: apoptosis through mitochondrial- dependent and -independent pathways. Oncogene 20:2122–2133CrossRefGoogle Scholar
  109. Teixeira C, Reed JC, Pratt MAC (1995) Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 protooncogene expression in human breast cancer cells. Cancer Res 55:3902–3907PubMedGoogle Scholar
  110. Thornberry NA, Rano TA, Peterson EP et al (1997) A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J Biol Chem 272:17907–17911CrossRefPubMedGoogle Scholar
  111. Varfolomeev EE, Ashkenazi A (2004) Tumor necrosis factor: an apoptosis JuNKie? Cell 116(4):491–497CrossRefPubMedGoogle Scholar
  112. Vegran F, Boidot R, Oudin C et al (2006) Overexpression of caspase-3s splice variant in locally advanced breast carcinoma is associated with poor response to neoadjuvant chemotherapy. Clin Cancer Res 12:5794–5800CrossRefPubMedGoogle Scholar
  113. Veis DJ, Sorenson CM, Shutter JR et al (1993) Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75:229–240CrossRefPubMedGoogle Scholar
  114. Vucic D, Fairbrother WJ (2007) The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 13(20):5995–6000CrossRefPubMedGoogle Scholar
  115. Wagner KU, Claudio E, Rucker EB III et al (2000) Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development 127:4949–4958PubMedGoogle Scholar
  116. Wallach D, Varfolomeev EE, Malinin NL et al (1999) Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol 17:331–367CrossRefPubMedGoogle Scholar
  117. Willis S, Day CL, Hinds MG et al (2003) The Bcl-2-regulated apoptotic pathway. J Cell Sci 116(20):4053–4056CrossRefPubMedGoogle Scholar
  118. Wingo PA, Tong T, Bolden S (1995) Cancer statistics, 1995. CA Cancer J Clin 45:8–30CrossRefPubMedGoogle Scholar
  119. Wittmann S, Bali P, Donapaty S et al (2003) Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res 63:93–99PubMedGoogle Scholar
  120. Wojciechowski J, Horky M, Gueorguieva M et al (2003) Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells. Int J Cancer 106:486–495CrossRefPubMedGoogle Scholar
  121. Wu J (1996) Apoptosis and angiogenesis: two promising tumor markers in breast cancer. Anticancer Res 16:2233–2240PubMedGoogle Scholar
  122. Yang J, Liu X, Bhalla K et al (1997) Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275:1129–1132CrossRefPubMedGoogle Scholar
  123. Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9:47–59CrossRefPubMedGoogle Scholar
  124. Zhang G-J, Kimijima I, Onda M et al (1999) Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-XL, without alteration of p53 protein levels. Clin Cancer Res 5:2971–2977PubMedGoogle Scholar
  125. Zhao YX, Lajoie G, Zhang H et al (2000) Tumor necrosis factor receptor p55- deficient mice respond to acute Yersinia enterocolitica infection with less apoptosis and more effective host resistance. Infect Immun 68:1243–1251CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  1. 1.Department of Pharmaceutical TechnologyJadavpur UniversityKolkata-32India

Personalised recommendations